10th November 2016
article written by
Cell Medica

Cell Medica and Baylor College of Medicine expand partnership to develop allogeneic CAR-NKT cells for cancer treatment

Cell Medica and Baylor College of Medicine expand partnership to develop allogeneic CAR-NKT cells for cancer treatment London, UK and Houston, TX – November 10, 2016 – Cell Medica, a leader in cellular immunotherapy for cancer, has expanded its partnership with Baylor College of Medicine (‘Baylor’) to develop an off-the-shelf allogeneic cell therapy, taking advantage […]

Read Full Article
24th August 2016
article written by
Cell Medica

Cell Medica and UCL collaborate to develop modified T cell receptor products for the treatment of cancer

Cell Medica and UCL collaborate to develop modified T cell receptor products for the treatment of cancer London, UK – August 24, 2016 – Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, has signed a research collaboration with UCL (University College London) aiming to utilize UCL’s novel T […]

Read Full Article
20th July 2016
article written by
Cell Medica

Lead cancer immunotherapy candidate granted EU orphan drug designations

Lead cancer immunotherapy candidate granted EU orphan drug designations London, UK– July 20, 2016.   Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, has received European Commission orphan drug designations for CMD-003 (baltaleucel-T) as a treatment for extranodal NK/T-cell lymphoma, nasal type, and post-transplant lymphoproliferative disorder. CMD-003 is […]

Read Full Article
12th July 2016
article written by
Cell Medica

Cell Medica acquires Delenex Therapeutics

Cell Medica acquires Delenex Therapeutics London, UK– July 12, 2016.   Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. The acquisition will […]

Read Full Article